These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30180867)

  • 1. ONE SHOT - single shot radiotherapy for localized prostate cancer: study protocol of a single arm, multicenter phase I/II trial.
    Zilli T; Scorsetti M; Zwahlen D; Franzese C; Förster R; Giaj-Levra N; Koutsouvelis N; Bertaut A; Zimmermann M; D'Agostino GR; Alongi F; Guckenberger M; Miralbell R
    Radiat Oncol; 2018 Sep; 13(1):166. PubMed ID: 30180867
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ONE SHOT - single shot radiotherapy for localized prostate cancer: 18-month results of a single arm, multicenter phase I/II trial.
    Zilli T; Franzese C; Guckenberger M; Giaj-Levra N; Mach N; Koutsouvelis N; Achard V; Mcdonald A; Alongi F; Scorsetti M; Constantin G; Bertaut A; Miralbell R
    Radiother Oncol; 2024 May; 194():110181. PubMed ID: 38403022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional imaging guided stereotactic ablative body radiotherapy (SABR) with focal dose escalation and bladder trigone sparing for intermediate and high-risk prostate cancer: study protocol for phase II safo trial.
    Zapatero A; Castro P; Roch M; Carnero PR; Carroceda S; Rosciupchin AES; Hernández SH; Cogorno L; Iturriaga AG; García DB
    Radiat Oncol; 2024 May; 19(1):54. PubMed ID: 38702761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Magnetic resonance imaging-guided stereotactic body radiotherapy for prostate cancer (mirage): a phase iii randomized trial.
    Ma TM; Lamb JM; Casado M; Wang X; Basehart TV; Yang Y; Low D; Sheng K; Agazaryan N; Nickols NG; Cao M; Steinberg ML; Kishan AU
    BMC Cancer; 2021 May; 21(1):538. PubMed ID: 33975579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single fraction urethra-sparing prostate cancer SBRT: Phase I results of the ONE SHOT trial.
    Zilli T; Franzese C; Bottero M; Giaj-Levra N; Förster R; Zwahlen D; Koutsouvelis N; Bertaut A; Blanc J; Roberto D'agostino G; Alongi F; Guckenberger M; Scorsetti M; Miralbell R
    Radiother Oncol; 2019 Oct; 139():83-86. PubMed ID: 31431369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GETUG-AFU 31: a phase I/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol.
    Pasquier D; Le Deley MC; Tresch E; Cormier L; Duterque M; Nenan S; Lartigau E
    BMJ Open; 2019 Aug; 9(8):e026666. PubMed ID: 31377694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
    Wolfe S; Diven MA; Marciscano AE; Zhou XK; Kishan AU; Steinberg ML; Miccio JA; Camilleri P; Nagar H
    BMC Cancer; 2023 Sep; 23(1):923. PubMed ID: 37777738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter prospective phase II study of postoperative hypofractionated stereotactic body radiotherapy (SBRT) in the treatment of early-stage oropharyngeal and oral cavity cancers with high risk margins: the STEREO POSTOP GORTEC 2017-03 trial.
    Biau J; Thivat E; Millardet C; Saroul N; Pham-Dang N; Molnar I; Pereira B; Durando X; Bourhis J; Lapeyre M
    BMC Cancer; 2020 Aug; 20(1):730. PubMed ID: 32758188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-a-week or every-other-day urethra-sparing prostate cancer stereotactic body radiotherapy, a randomized phase II trial: 18 months follow-up results.
    Zilli T; Jorcano S; Bral S; Rubio C; Bruynzeel AME; Oliveira A; Abacioglu U; Minn H; Symon Z; Miralbell R
    Cancer Med; 2020 May; 9(9):3097-3106. PubMed ID: 32160416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS).
    Thureau S; Marchesi V; Vieillard MH; Perrier L; Lisbona A; Leheurteur M; Tredaniel J; Culine S; Dubray B; Bonnet N; Asselain B; Salleron J; Faivre JC
    BMC Cancer; 2021 Feb; 21(1):117. PubMed ID: 33541288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Efficacy of Virtual Prostatectomy With Single-Dose Radiotherapy in Patients With Intermediate-Risk Prostate Cancer: Results From the PROSINT Phase 2 Randomized Clinical Trial.
    Greco C; Pares O; Pimentel N; Louro V; Santiago I; Vieira S; Stroom J; Mateus D; Soares A; Marques J; Freitas E; Coelho G; Seixas M; Lopez-Beltran A; Fuks Z
    JAMA Oncol; 2021 May; 7(5):700-708. PubMed ID: 33704378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SABR-Dual: a phase II/III trial of two-fraction versus five-fraction stereotactic radiotherapy for localized low- and favorable intermediate-risk prostate cancer.
    Fredman E; Icht O; Moore A; Bragilovski D; Kindler J; Golan S; Limon D
    BMC Cancer; 2024 Apr; 24(1):431. PubMed ID: 38589860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes.
    Fuller DB; Falchook AD; Crabtree T; Kane BL; Medbery CA; Underhill K; Gray JR; Peddada A; Chen RC
    Eur Urol Oncol; 2018 Dec; 1(6):540-547. PubMed ID: 31158102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The march toward single-fraction stereotactic body radiotherapy for localized prostate cancer-Quo Vadimus?
    Ong WL; Loblaw A
    World J Urol; 2023 Dec; 41(12):3485-3491. PubMed ID: 37921936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypo-fractionated SBRT for localized prostate cancer: a German bi-center single treatment group feasibility trial.
    Jiang P; Krockenberger K; Vonthein R; Tereszczuk J; Schreiber A; Liebau S; Huttenlocher S; Imhoff D; Balermpas P; Keller C; Dellas K; Baumann R; Rödel C; Hildebrandt G; Jünemann KP; Merseburger AS; Katz A; Ziegler A; Blanck O; Dunst J
    Radiat Oncol; 2017 Aug; 12(1):138. PubMed ID: 28821268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PROstate Multicentre External beam radioTHErapy Using a Stereotactic boost: the PROMETHEUS study protocol.
    Richardson M; Sidhom M; Gallagher S; Grand M; Pryor D; Bucci J; Wilton L; Arumugam S; Keats S; Martin JM
    BMC Cancer; 2018 May; 18(1):588. PubMed ID: 29793444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
    Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
    Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body-radiotherapy boost dose of 18 Gy vs 21 Gy in combination with androgen-deprivation therapy and whole-pelvic radiotherapy for intermediate- or high-risk prostate cancer: a study protocol for a randomized controlled, pilot trial.
    Kim YJ; Ahn H; Kim CS; Lee JL; Kim YS
    Trials; 2018 Apr; 19(1):212. PubMed ID: 29609646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring All Avenues for Radiotherapy in Oligorecurrent Prostate Cancer Disease Limited to Lymph Nodes: A Systematic Review of the Role of Stereotactic Body Radiotherapy.
    Ponti E; Lancia A; Ost P; Trippa F; Triggiani L; Detti B; Ingrosso G
    Eur Urol Focus; 2017 Dec; 3(6):538-544. PubMed ID: 28801240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial.
    De Cock L; Draulans C; Pos FJ; Isebaert S; De Roover R; van der Heide UA; Smeenk RJ; Kunze-Busch M; van der Voort van Zyp J; de Boer H; Kerkmeijer LGW; Haustermans K
    Radiother Oncol; 2023 Aug; 185():109713. PubMed ID: 37178932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.